Product news

Share this article:
Neurocrine Biosciences said the FDA has requested additional data regarding the company's New Drug Application for indiplon 5 mg and 10 mg capsules for the treatment of insomnia. The request comes six months after Neurocrine resubmitted its application for 5-mg and 10-mg doses. The FDA denied approval in May 2006 over issues with the 15-milligram dose, which was expected to bring in the bulk of Neurocrine's revenue after approval. Pfizer terminated a partnership with Neurocrine over indiplon in June 2006. Neurocrine later announced it was cutting its field sales force, followed by 100 workers at its company headquarters. The FDA's latest approvable letter request states indiplon is approvable in the two requested doses, pending the submission of additional clinical trial and preclinical study data. The requirements include an objective/subjective clinical trial in the elderly, a safety study, and preclinical study data evaluating indiplon during the third trimester of pregnancy, Neurocrine said.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.